Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $248 | $0 | $0 | $0 |
| Enterprise Value | $248 | $0 | $0 | $0 |
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | – | $0 | -$0 | -$0 |
| % Margin | – | 70.8% | – | – |
| EBITDA | – | -$0 | -$0 | -$0 |
| % Margin | – | -1,333.5% | – | – |
| Net Income | – | -$0 | -$0 | $0 |
| % Margin | – | -1,338.8% | – | – |
| EPS Diluted | – | -0.55 | -1.5 | 0.72 |
| % Growth | – | 63.3% | -308.3% | – |
| Operating Cash Flow | – | -$0 | -$0 | -$0 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | -$0 | -$0 | -$0 |